Mesoblast, a regenerative medicines developer with a market capitalization of $3.1 billion, is set to be included in the ...

In today’s news, APRA’s new rules target bank and super boards, the Gold Coast records its “highest ever” wave as Cyclone Alfred barrels in, and Donald Trump sets off a chain reaction across global ...

Shares lower, oil price slump hits Santos, Woodside; Greg Foran resigns as Air NZ CEO; Myer rallies; Amcor hints at exec ...

These shares are falling more than most on Thursday. But why? The post Why Appen, Mesoblast, Rio Tinto, and Woodside shares ...

Mesoblast shares fell by more than 5% in morning trade after the dual-listed biotech company was added to the ASX 200 index.

The ASX took a hit on Thursday, with the energy sector sinking. Meanwhile gold miners shone and Star casino was handed a ...

ASX slipped with energy stocks down, Amcor fell on restructure news, Mesoblast dropped after joining the ASX 200.

Here's why analysts at Bell Potter think that Mesoblast Ltd (ASX: MSB) shares could still be cheap despite rallying hard since this time last ...

Tenosynovial giant cell tumor, also known as pigmented villonodular synovitis (PVNS) or giant cell tumor of the tendon sheath ...

Mesoblast Limited ( ASX:MSB ) shareholders might be concerned after seeing the share price drop 27% in the last ...

Regenerative medicine, a rapidly advancing field, can be generally defined as a therapeutic methodology for the repair, ...

Q2 2025 Earnings Call Transcript February 28, 2025 Silviu Itescu: Good morning, everybody. I’m Silviu Itescu. I’m the Chief ...